The Impact of HCC Surveillance on Tumor Features and Receipt of Curative Therapy: A Focus on Chronic Hepatitis B and MASLD
Journal of Gastroenterology and Hepatology · 2026-11 · 41 (11) · 3539-3546
DOI: 10.1111/jgh.70705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 09.09.2026. Verfasst von Shao-Li Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Ta…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Taiwan University Hospital, National Science and Technology Council, Taiwan, Liver Disease Prevention and Treatment Research Foundation, Taiwan.
Abstract (Originalsprache)
Background
As hepatocellular carcinoma (HCC) etiologies shift from viral to non‐viral, many at‐risk patients lack surveillance in real‐world practice. This study characterizes the clinical features and receipt of curative therapy in HCC patients with and without surveillance.
Methods
A retrospective cohort study was conducted at National Taiwan University Hospital (2015–2025). Patients newly diagnosed with HCC who had not undergone regular surveillance ( n = 50) were compared with a consecutive surveillance‐diagnosed cohort ( n = 100). Subgroup analyses were performed in patients with chronic hepatitis B and MASLD.
Results
Compared with the surveillance group, non‐surveillance patients had higher baseline liver enzymes and alpha‐fetoprotein levels, larger tumors, higher rates of multifocal tumors, and more frequent vascular invasion. Symptomatically diagnosed non‐surveillance patients also presented with more advanced disease. Multivariable analysis identified surveillance as a strong independent predictor of receiving curative therapy (odds ratio [OR]: 17.78; 95% confidence interval [CI]: 5.56–56.88, p < 0.001). In the chronic hepatitis B subgroup, both surveillance (OR 26.79, 95% CI: 6.80–106.00, p < 0.001) and higher BMI (OR 1.18, 95% CI: 1.05–1.33, p = 0.005) were independent predictors of curative therapy. The rate of HBV carriers (72%), cirrhosis (54%), and MASLD (14%) remained substantial within the non‐surveillance group.
Conclusion
HCC surveillance was associated with earlier stage at diagnosis and independently predicted receipt of curative therapy; higher BMI was an additional predictor in the HBV subgroup. Most patients diagnosed without surveillance had underlying HBV infection, cirrhosis or MASLD, and presented with more advanced disease and lower rates of curative therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University BioMedical Park Hospital Chu-Tung Campus, Hsinchu County, Taiwan.
- Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Beihu Branch, Taipei, Taiwan.
- Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine Taipei, Taiwan.
ORCID-Profile: Shao-Li Huang, Chun-Jen Liu, Tung-Hung Su, Jia-Horng Kao
Förderung
- National Taiwan University Hospital
- National Science and Technology Council, Taiwan
- Liver Disease Prevention and Treatment Research Foundation, Taiwan
- National Science and Technology Council
Zitieren
APA
Huang, S. L., Chen, H. A., Liao, C. H., Hu, S. C., Huang, S. C., Liu, C. J., Su, T. H., & Kao, J. H. (2026). The Impact of HCC Surveillance on Tumor Features and Receipt of Curative Therapy: A Focus on Chronic Hepatitis B and MASLD. Journal of Gastroenterology and Hepatology, 41(11), 3539-3546. https://doi.org/10.1111/jgh.70705
Vancouver
Huang SL, Chen HA, Liao CH, Hu SC, Huang SC, Liu CJ, et al. The Impact of HCC Surveillance on Tumor Features and Receipt of Curative Therapy: A Focus on Chronic Hepatitis B and MASLD. Journal of Gastroenterology and Hepatology. 2026;41(11):3539-3546. doi:10.1111/jgh.70705
BibTeX
@article{Huang2026,
author = {Huang, Shao-Li and Chen, Hsi-An and Liao, Chun-Hsun and Hu, Shih-Chi and Huang, Shang-Chin and Liu, Chun-Jen and Su, Tung-Hung and Kao, Jia-Horng},
title = {The Impact of HCC Surveillance on Tumor Features and Receipt of Curative Therapy: A Focus on Chronic Hepatitis B and MASLD},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {11},
pages = {3539--3546},
doi = {10.1111/jgh.70705}
}
EUVIMED